中西药联合治疗良性前列腺增生症的优化方案研究

发布时间：2018-02-03 12:06

本文关键词： 良性前列腺增生症中西药联合优化方案　出处：《黑龙江中医药大学》2014年硕士论文　论文类型：学位论文

【摘要】：目的：通过比较癃闭舒胶囊联合甲磺酸多沙唑嗪、单纯癃闭舒胶囊、单纯甲磺酸多沙唑嗪治疗良性前列腺增生症(BPH)的临床疗效,探索中西药联合治疗本病的作用机理,以优化BPH的临床治疗方案。方法：90例受试者均来自黑龙江中医药大学附属第二医院男科门诊。经询问病史、B超检查、直肠指检、尿流率测定等检查确诊为良性前列腺增生症的患者。用SPSS软件产生的随机数字表,进行入组病例的分配。随机分为A、B、C三个组别,每组各30例。A组(对照I组)甲磺酸多沙唑嗪和癃闭舒胶囊安慰剂；B组(治疗组)甲磺酸多沙唑嗪联合癃闭舒胶囊；C组(对照II组)甲磺酸多沙唑嗪安慰剂和癃闭舒胶囊。甲磺酸多沙唑嗪(每次0.9g,每日2次),癃闭舒胶囊(每次2mg,每日一次),安慰剂用法同原药。治疗后对临床症状、IPSS、最大尿流率、残余尿量、前列腺体积等指标进行对照分析。结果：1.本研究共入选90例患者,脱落和剔除病例18例,最后有效病例72例。其中A组23例,B组23例,C组26例。A组总有效为86.96%；B组总有效91.30%；C组总有效率为76.92%。2.三组治疗前后的国际前列腺评分表(IPSS)、中医症状评分、最大尿流率(Qmax)、生活质量评分(Q01)均有明显改善,有统计学意义(P0.05)。3.前列腺体积(PV)和残余尿量(RU)治疗前后无明显改善,差异无统计学意义(P0.05)。结论：1.癃闭舒胶囊联合甲磺酸多沙唑嗪可显著降低BPH患者的国际前列腺评分(IPSS),明显改善BPH患者的排尿困难、夜尿频多、尿线变细和少腹胀痛等临床症状。2.癃闭舒胶囊联合甲磺酸多沙唑嗪可以明显提高BPH患者的最大尿流率和生活质量。3.三组治疗方案在减少残余尿量、缩小前列腺体积方面疗效均不明显。4.三组治疗方案在研究过程中均未出现明显不良反应。
[Abstract]:Objective: to compare the clinical effects of Longbishu capsule combined with doxazosin mesylate, Longbishu capsule alone and doxazosin mesylate alone in the treatment of benign prostatic hyperplasia (BPH). To explore the mechanism of combined Chinese and western medicine for the treatment of this disease in order to optimize the clinical treatment of BPH. Methods 90 subjects were collected from Department of andrology, second affiliated Hospital of Heilongjiang University of traditional Chinese Medicine. The patients diagnosed as benign prostatic hyperplasia (BPH) were divided into three groups randomly by SPSS software. Each group consisted of 30 patients in group A (control group I) and placebo in doxazosin mesylate and Longbushu capsules. Group B (treatment group): doxazosin mesylate combined with Longbishu capsule; Group C (control group II): doxazosin mesylate placebo and longbast capsule. Doxazosin mesylate (0.9g / d, twice daily), Longbishu capsule (2mg / day). After treatment, the clinical symptoms of IPSS, maximum flow rate, residual urine volume, prostate volume and so on were compared and analyzed. Results 1. In this study, 90 patients were selected, 18 cases were dropped off and 18 cases were excluded, and 72 cases were effective, 23 cases were in Group A and 23 cases were in Group B. The total effective rate of group C (26 cases) was 86.96; The total effective rate of group B was 91.30%; The total effective rate of group C was 76.92. The international prostate scoring scale before and after treatment was IPSS, TCM symptom score, maximum urinary flow rate (Qmax.). Q01), there was no significant improvement before and after treatment (P 0.05) and residual urine volume (RUU) before and after treatment. The difference was not statistically significant (P 0.05). Conclusion 1. Longbishu capsule combined with doxazosin mesylate can significantly reduce the international prostatic score of BPH patients and improve the dysuria of BPH patients with more frequent nocturnal urination. Longbeshu capsule combined with doxazosin mesylate can significantly improve the maximum urinary flow rate and quality of life of patients with BPH .3.The three treatment groups in reducing residual urine volume. The effect of reducing prostate volume was not obvious. 4. No significant adverse reactions were observed in the three treatment groups in the course of the study.
【学位授予单位】：黑龙江中医药大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R697.3

【参考文献】